By continuing to use the site you agree to our Privacy & Cookies policy

Your browser seems to have cookies disabled. For the best experience of this website, please enable cookies in your browser.


Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


NICE recommends fingolimod on NHS for multiple sclerosis patients

NICE has given the all clear for fingolimod (Gilenya) - a pill that can help adults suffering from highly active relapsing-remitting multiple sclerosis (RRMS).

Fingolimod is the first pill-based medicine that can help reduce the number of relapses as other treatments are administered by injection.

NICE has recommended using fingolimod on adult patients who, despite taking beta interferons, are showing an unchanged or increased relapse rate or ongoing severe relapses compared to the previous year.

Around 27,500 people in England and Wales are effected by RRMS which is characterised by periods when symptoms worsen and then improve.

Professor Carole Longson, director of the Health Technology Evaluation Centre at NICE said: “Our committee concluded that fingolimod is a valuable new therapy for highly active relapsing-remitting multiple sclerosis.

“Multiple sclerosis can be a disabling condition and so we hope that this novel treatment will help to reduce relapses for these people.”


Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!